ArticleAddiction science & clinical practice2023
Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
Article in Addiction science & clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Treating Opioid Use Disorder With Methadone in Pharmacies.JAMA network open · 2026Article
- Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: A scoping review.Drug and alcohol dependence reports · 2026Review
- Implementation challenges and opportunities in decentralized methadone service delivery.BMC health services research · 2025Article
- Implementation Challenges and Opportunities in Decentralized Methadone Service Delivery.Research square · 2025Article
- Key-Informant Perspectives On Pharmacy-Based Methadone Treatment For Opioid Use Disorder In The US.Health affairs (Project Hope) · 2025Article
- Community pharmacy's role in dispensing androgens and supporting harm reduction amid current policy dilemmas.Substance abuse treatment, prevention, and policy · 2025Article
- Pharmacy-based preventive services for opioid use disorder: a survey of U.S. pharmacists.Addiction science & clinical practice · 2024Article
- "Tethered to this ball and chain": Women's perspectives on bodily agency within opioid treatment programs.The International journal on drug policy · 2024Article
- CTN-0138: adaptation, implementation, and cluster randomized trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool-a protocol paper.Addiction science & clinical practice · 2024Article
- Privacy in Community Pharmacies in Saudi Arabia: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2024Article
- Exploring the role of community pharmacies as a harm reduction environment for anabolic-androgenic steroid consumers: triangulating the perspectives of consumers and pharmacists.Harm reduction journal · 2024Article
- Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.Substance abuse treatment, prevention, and policy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPharmacy administration and dispensing of methadone treatment for opioid use disorder (PADMOUD) may address inadequate capability of opioid treatment programs (OTPs) in the US by expanding access to methadone at community pharmacies nationally. PADMOUD is vastly underutilized in the US. There is no published US study on OUD patients' perspectives on PADMOUD. Data are timely and needed to inform the implementation of PADMOUD in the US to address its serious opioid overdose crisis.
methodsPatient participants of the first completed US trial on PADMOUD through electronic prescribing for methadone (parent study) were interviewed to explore implementation-related factors for PADMOUD. All 20 participants of the parent study were invited to participate in this interview study. Each interview was recorded and transcribed verbatim. Thematic analysis was conducted to identify emergent themes.
resultsSeventeen participants completed the interview. Patients' perspectives on PADMOUD were grouped into five areas. Participants reported feasibility of taking the tablet formulation of methadone at the pharmacy and identified benefits from PADMOUD (e.g., better access, efficiency, convenience) compared with usual care at the OTP. Participants perceived support for PADMOUD from their family/friends, OTP staff, and pharmacy staff. PADMOUD was perceived to be a great option for stable patients with take-home doses and those with transportation barriers. The distance (convenience), office hours, and the cost were considered factors most influencing their decision to receive methadone from a pharmacy. Nonjudgmental communication, pharmacists' training on methadone treatment, selection of patients (stable status), workflow of PADMOUD, and protection of privacy were considered key factors for improving operations of PADMOUD.
conclusionThis study presents the first findings on patient perspectives on PADMOUD. Participants considered pharmacies more accessible than OTPs, which could encourage more people to receive methadone treatment earlier and help transition stable patients from an OTP into a local pharmacy. The findings have timely implications for informing implementation strategies of PADMOUD that consider patients' views and needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.